← Back to Search

Implant

Baerveldt 350 implant for Glaucoma

N/A
Waitlist Available
Led By Leon Herndon, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and year 1
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the outcomes of two different types of eye surgery. One surgery uses the Baerveldt implant and the other uses the Ahmed ClearPath implant.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and year 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and year 1 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in Humphrey Visual Field (HVF)
Change in Retinal Nerve Fiber Layer (RNFL)
Change in Thickness of the Cornea as Measured by Pachymetry
Other study objectives
Change in Motility Exam (Hess Screen Test)
Change in Motility Exam (Stereo Test)
Change in Motility Exam (Worth 4-dot)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Baerveldt 350 implantActive Control1 Intervention
Group II: Ahmed ClearPath 350 implantActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,451 Previous Clinical Trials
3,067,147 Total Patients Enrolled
15 Trials studying Glaucoma
2,850 Patients Enrolled for Glaucoma
Leon Herndon, MDPrincipal InvestigatorDuke University
3 Previous Clinical Trials
198 Total Patients Enrolled
2 Trials studying Glaucoma
100 Patients Enrolled for Glaucoma
~16 spots leftby Oct 2025